FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3032731000> ?p ?o ?g. }

• W3032731000 endingPage "e0233705" @default.
• W3032731000 startingPage "e0233705" @default.
• W3032731000 abstract "Paricalcitol, a new vitamin D receptor activator (VDRA), is reported to be more effective than other VDRAs in reducing calcium and phosphorus levels in patients undergoing hemodialysis. However, the efficacy and safety of paricalcitol remain controversial. This analysis compares paricalcitol with other VDRAs in patients undergoing hemodialysis. We searched the Cochrane Library, PubMed, EMBASE, Web of Science, and CNKI up to April 22, 2019. Standardized mean difference (SMD), risk ratio (RR) and 95% confidence interval (CI) values were estimated to compare the outcomes of the groups. Two reviewers extracted data and assessed trial quality independently. All statistical analyses were performed using the standard statistical procedures of RevMan 5.2 and Stata 12.0. Fifteen studies (N = 110,544) were included in this meta-analysis. Of these studies, 11 were randomized controlled trials (RCTs) and 4 were non-randomized studies of interventions (NRSIs). Patients receiving paricalcitol experienced better overall survival (OS) than patients receiving other VDRAs, with a pooled hazard ratio of 0.86 (95% CI 0.80–0.91; P < 0.00001). Intact parathyroid hormone (iPTH) levels were significantly reduced in the paricalcitol group compared to the group receiving other VDRAs, with a pooled SMD of -0.53 (95% CI -0.89– -0.16; P = 0.004). There was a significant increase in serum calcium levels from baseline in the paricalcitol group compared to the other VDRAs group when limiting the analysis to RCTs, with a pooled SMD of 2.14 (95% CI 0.90–3.38; P = 0.0007). Changes in serum calcium levels were significantly lower in the paricalcitol group when the analysis was limited to NRSIs, with a pooled SMD of -0.85 (95% CI -1.34–-0.35; P = 0.0008). The NSRI analysis also showed a significant reduction in serum phosphorus levels in the paricalcitol group, with a pooled SMD of -0.57 (95% CI -1.00–-0.13; P = 0.01). No significant differences were observed in the incidence of hypercalcemia, hyperphosphatemia, or adverse events. Generally, paricalcitol seems superior to other VDRAs in reducing mortality and iPTH levels in patients undergoing hemodialysis. However, the comparative effectiveness of paricalcitol in reducing serum calcium and phosphorus levels needs further exploration. No significant difference was found in the rate of adverse events." @default.
• W3032731000 created "2020-06-05" @default.
• W3032731000 creator A5004461231 @default.
• W3032731000 creator A5014528914 @default.
• W3032731000 creator A5014837150 @default.
• W3032731000 creator A5082940088 @default.
• W3032731000 date "2020-05-29" @default.
• W3032731000 modified "2023-10-14" @default.
• W3032731000 title "A comparative analysis of the efficacy and safety of paricalcitol versus other vitamin D receptor activators in patients undergoing hemodialysis: A systematic review and meta-analysis of 15 randomized controlled trials" @default.
• W3032731000 cites W1835676912 @default.
• W3032731000 cites W1912925321 @default.
• W3032731000 cites W1963332039 @default.
• W3032731000 cites W1967198595 @default.
• W3032731000 cites W1967330581 @default.
• W3032731000 cites W1982228885 @default.
• W3032731000 cites W1997341767 @default.
• W3032731000 cites W2003838980 @default.
• W3032731000 cites W2013997927 @default.
• W3032731000 cites W2019789856 @default.
• W3032731000 cites W2021514219 @default.
• W3032731000 cites W2025589168 @default.
• W3032731000 cites W2035221187 @default.
• W3032731000 cites W2038986027 @default.
• W3032731000 cites W2055220862 @default.
• W3032731000 cites W2074826032 @default.
• W3032731000 cites W2077677810 @default.
• W3032731000 cites W2080387599 @default.
• W3032731000 cites W2082042666 @default.
• W3032731000 cites W2083875067 @default.
• W3032731000 cites W2087806333 @default.
• W3032731000 cites W2097105350 @default.
• W3032731000 cites W2098923148 @default.
• W3032731000 cites W2100237555 @default.
• W3032731000 cites W2101687723 @default.
• W3032731000 cites W2105407962 @default.
• W3032731000 cites W2105417592 @default.
• W3032731000 cites W2107207648 @default.
• W3032731000 cites W2113356410 @default.
• W3032731000 cites W2114902110 @default.
• W3032731000 cites W2116475791 @default.
• W3032731000 cites W2116618632 @default.
• W3032731000 cites W2127561755 @default.
• W3032731000 cites W2128372431 @default.
• W3032731000 cites W2132644547 @default.
• W3032731000 cites W2136486000 @default.
• W3032731000 cites W2143311403 @default.
• W3032731000 cites W2150000105 @default.
• W3032731000 cites W2156098321 @default.
• W3032731000 cites W2161701454 @default.
• W3032731000 cites W2162732991 @default.
• W3032731000 cites W2273875352 @default.
• W3032731000 cites W2315590268 @default.
• W3032731000 cites W2328615536 @default.
• W3032731000 cites W2425433868 @default.
• W3032731000 cites W2588681363 @default.
• W3032731000 cites W2610204288 @default.
• W3032731000 cites W2746295793 @default.
• W3032731000 cites W2756578555 @default.
• W3032731000 cites W2786724349 @default.
• W3032731000 cites W2922976514 @default.
• W3032731000 cites W2991792334 @default.
• W3032731000 cites W4211046201 @default.
• W3032731000 cites W4231923733 @default.
• W3032731000 doi "https://doi.org/10.1371/journal.pone.0233705" @default.
• W3032731000 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7259607" @default.
• W3032731000 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32470067" @default.
• W3032731000 hasPublicationYear "2020" @default.
• W3032731000 type Work @default.
• W3032731000 sameAs 3032731000 @default.
• W3032731000 citedByCount "10" @default.
• W3032731000 countsByYear W30327310002020 @default.
• W3032731000 countsByYear W30327310002021 @default.
• W3032731000 countsByYear W30327310002022 @default.
• W3032731000 countsByYear W30327310002023 @default.
• W3032731000 crossrefType "journal-article" @default.
• W3032731000 hasAuthorship W3032731000A5004461231 @default.
• W3032731000 hasAuthorship W3032731000A5014528914 @default.
• W3032731000 hasAuthorship W3032731000A5014837150 @default.
• W3032731000 hasAuthorship W3032731000A5082940088 @default.
• W3032731000 hasBestOaLocation W30327310001 @default.
• W3032731000 hasConcept C124490489 @default.
• W3032731000 hasConcept C126322002 @default.
• W3032731000 hasConcept C126894567 @default.
• W3032731000 hasConcept C168563851 @default.
• W3032731000 hasConcept C2776478404 @default.
• W3032731000 hasConcept C2778063415 @default.
• W3032731000 hasConcept C2778838027 @default.
• W3032731000 hasConcept C2779524405 @default.
• W3032731000 hasConcept C2781208988 @default.
• W3032731000 hasConcept C44249647 @default.
• W3032731000 hasConcept C519063684 @default.
• W3032731000 hasConcept C71924100 @default.
• W3032731000 hasConcept C95190672 @default.
• W3032731000 hasConceptScore W3032731000C124490489 @default.
• W3032731000 hasConceptScore W3032731000C126322002 @default.
• W3032731000 hasConceptScore W3032731000C126894567 @default.
• W3032731000 hasConceptScore W3032731000C168563851 @default.
• W3032731000 hasConceptScore W3032731000C2776478404 @default.

• next